No Evidence of Disease Activity in MS With Ozanimod

News Network | <b>American Academy of Neurology 2022: Multiple Sclerosis Highlights</b>

Ludwig Kappos, MD, FEAN, FAAN, provided insight on a new analysis that showed greater proportions of patients achieving no evidence of disease activity on ozanimod compared with interferon ß-1a.

Ludwig Kappos, MD, FEAN, FAAN: This is about the follow-up of controlled studies with ozanimod in relapsing multiple sclerosis. These studies had a controlled phase where once weekly, intramuscularly ozanimod was compared with interferon ß-1a. It had a long follow-up of several years, with a high retention rate of the initial patients who were randomized in the controlled part. Essentially, the positive effects that were observed in the controlled phase were sustained over time. In this analysis that we presented, we looked at the occurrence of evidence of disease activity in these patients. If in the duration or during the follow-up, we looked for any signs of relapse or new lesions on MRI. We also looked at disability progression that was confirmed at least 3 months later. We see that the effects in the first year were repeated over time, and that a significant number of patients remained disease activity free under these quite strict criteria. Those who had evidence of disease activity, mainly had this through MRIs, so through lesions that occurred in their regularly repeated and standardized assessments.

Transcript edited for clarity.